2019 Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 102 pages | ID: 2B69F69CE5BEN
VPAResearch

Abstracts

The global clinical trial report- “2019 Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Juvenile Myelomonocytic Leukemia (JMML). It presents in-depth analysis of Juvenile Myelomonocytic Leukemia (JMML) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Juvenile Myelomonocytic Leukemia (JMML).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Juvenile Myelomonocytic Leukemia (JMML) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Juvenile Myelomonocytic Leukemia (JMML)

The research work is prepared through extensive and continuous research on Juvenile Myelomonocytic Leukemia (JMML) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Juvenile Myelomonocytic Leukemia (JMML) patients are identified
• The report includes panorama of Juvenile Myelomonocytic Leukemia (JMML) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Juvenile Myelomonocytic Leukemia (JMML) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Region
  2.2.2 Average Enrollment of Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Juvenile Myelomonocytic Leukemia (JMML) Treatment, 2019

3. REGION WISE JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) CLINICAL TRIALS

3.1 Asia Pacific Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Country
3.2 Europe Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Country
3.3 North America Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Country
3.4 Middle East and Africa Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Country
3.5 South and Central America Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Country

4. JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) CLINICAL TRIAL TRENDS

4.1 Start Year wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials
4.2 Phase wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials
4.3 Trial Status wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials
4.4 Trial Type wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials

5. JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Juvenile Myelomonocytic Leukemia (JMML) Trials by Year
5.2 Average Enrollment in Juvenile Myelomonocytic Leukemia (JMML) Trials by Phase
5.3 Average Enrollment in Juvenile Myelomonocytic Leukemia (JMML) Trials by Status
5.4 Average Enrollment in Juvenile Myelomonocytic Leukemia (JMML) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML) CLINICAL TRIALS

6.1 Juvenile Myelomonocytic Leukemia (JMML) Trials by Sponsor Type
6.2 Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.2 Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.3 Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase
7.4 Juvenile Myelomonocytic Leukemia (JMML) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Figure 7: North America – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Figure 9: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Phase
Figure 10: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Trial Status
Figure 11: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Type
Figure 12: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Sponsor Type
Figure 13: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials by Leading Sponsors
Figure 14: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Phase
Figure 15: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Trial Status
Figure 16: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Type
Figure 17: Juvenile Myelomonocytic Leukemia (JMML)- Average Enrolment by Type of Sponsors
Figure 18: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Table 5: Europe – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Table 7: North America – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Juvenile Myelomonocytic Leukemia (JMML) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Phase
Table 15: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Trial Status
Table 16: Juvenile Myelomonocytic Leukemia (JMML) Average Enrollment by Type
Table 17: Juvenile Myelomonocytic Leukemia (JMML)- Average Enrolment by Type of Sponsors
Table 18: Juvenile Myelomonocytic Leukemia (JMML)- Enrolment by Leading Sponsors